Latest Earnings Results: Q2 '26
Estimated EPS
$0.00
Reported EPS
$0.00
Surprise
+100%
Estimated Rev
$0.5M
Reported Rev
$0.29M
Surprise
-41.2%
• Reported GAAP EPS of $0.00 • Reported revenue of $0.29M down -3.33% YoY • BioLineRx is maintaining its cash runway guidance into the first half of 2027, supported by $13.1M in cash, cash equivalents, and short-term bank deposits as of June 30, 2026.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.38 | -- | -- | N/A |
Q2 '26 | $0.00 | $0.00 | 100.00% | EXPECTED |
Q1 '26 | -$1.04 | $0.00 | 100.00% | BEAT |
Q4 '25 | -$0.38 | -- | -- | N/A |
Q3 '25 | -$0.67 | $0.00 | 100.00% | BEAT |